STAT4 and diabetes mellitus: We hypothesize that Stat4 may be a final common pathway mediator of inflammatory damage that is important in normal aging, diabetes and AD, and that therapies that prevent Stat4 activation have potential as novel treatments for such slow, progressive neurodegenerative diseases.